Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A Review on Alzheimer's Disease


Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, India
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt.), Andhra Pradesh India, India
3 SIMS College of Pharmacy, Guntur, Andhra Pradesh, India
     

   Subscribe/Renew Journal


Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. More than 25 million people in the world today are affected by dementia, most suffering from Alzheimer's disease. There are three stages of the condition mild, moderate and severe. The symptoms are also varies from stage to stage. Some of the causes of this disease includes age, family history, Down's syndrome and vascular disease. Mainly it occurs due to presence of extracellular amyloid plaques and intracellular neurofibrillary tangles. Diagnosis can be done by using CT scan, MRI scan and Cognitive tests. Cholinesterase inhibitors and partial glutamate antagonists are used for the treatment. It can be prevented by performing some of activities like reading, writing and learning foreign languages.

Keywords

Alzheimer's Disease, Dementia, Down's Syndrome, Amyloid Plaques and Cholinesterase Inhibitors.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Berchtold NC, Cotman CW. Evolution in the Conceptualization of Dementia and Alzheimer's Disease: Greco-Roman Period to the 1960s. Neurobiol. Aging. 1998;19(3):173-89.

  • Brookmeyer R., Gray S., Kawas C.. Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset. American Journal of Public Health. 1998;88(9):1337-42.

  • Brookmeyer R, Johnson E, Ziegler-Graham K, MH Arrighi. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia. 2007 [Retrieved 2008-06- 18];3(3):186-91.

  • World population prospects: the 2006 revision, highlights [PDF]. 2007 [Retrieved 2008-08-2

  • Nistor M. Alpha- and Beta-secretase Activity as a Function of Age and Beta-amyloid in Down Syndrome and Normal Brain. Neurobiol Aging. 2007;28(10):1493-1506.

  • Lott IT, Head E. Alzheimer Disease and Down Syndrome: Factors in Pathogenesis. Neurobiol Aging. 2005;26(3):383-89

  • Hardy J, Allsop D. Amyloid Deposition as the Central Event in the Aetiology of Alzheimer's Disease. Trends Pharmacol. Sci.. 1991;12(10):383-88.

  • Polvikoski T. Apolipoprotein E, Dementia, and Cortical Deposition of Beta-amyloid Protein. N Engl J Med. 1995;333(19):1242-47.

  • Games D. Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein. Nature. 1995;373(6514):523-27.

  • Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein and Alzheimer's Disease. J Neurosci. 1996;16(18):5795-811.

  • Hsiao K. Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice. Science. 1996;274(5284):99-102.

  • Lauren J. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers. Nature. 2009; 457 (7233): 1128-32.

  • Nikolaev A, McLaughlin T, O'Leary D, Tessier-Lavigne M. APP Binds DR6 to Cause Axon Pruning and Neuron Death via Distinct Caspases. Nature. 19 February 2009;457(7232):981-989. Goedert M, Spillantini MG, Crowther RA. Tau Proteins and Neurofibrillary Degeneration. Brain Pathol. 1991;1(4):279-86.

  • Francis PT, Palmer AM, Snape M, Wilcock GK. The Cholinergic Hypothesis of Alzheimer's Disease: a Review of Progress. J. Neurol. Neurosurg. Psychiatr. 1999;66(2):137-47.

  • Shen ZX. Brain Cholinesterases: II. The Molecular and Cellular Basis of Alzheimer's Disease. Med Hypotheses. 2004;63(2):308- 21.

  • Iqbal K. Tau Pathology in Alzheimer Disease and Other Tauopathies. Biochim Biophys Acta. 2005;1739(2-3):198-210.

  • Chun W, Johnson GV. The Role of Tau Phosphorylation and Cleavage in Neuronal Cell Death. Front Biosci. 2007;12:733-56

  • Kotzbauer PT, Trojanowsk JQ, Lee VM. Lewy Body Pathology in Alzheimer's Disease. J Mol Neurosci. 2001;17(2):225-32

  • Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases. Neuromolecular Med.. 2003;4(1-2):21-36.

  • Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse Formation and Function is Modulated by the Amyloid Precursor Protein. J. Neurosci. 2006;26(27):7212-21.

  • Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of Amyloid Precursor Protein and its Fragments in Regulating Neural Activity, Plasticity and Memory. Prog. Neurobiol.. 2003; 70(1):1-32.

  • Bermejo-Pareja F, Benito-Leon J, Vega S, Medrano MJ, Roman GC. Incidence and subtypes of dementia in three elderly populations of central Spain. J. Neurol. Sci.. 2008; 264(1-2):63- 72.

  • Di Carlo A. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc. 2002; 50(1):41-8.

  • Andersen K. Gender Differences in the Incidence of AD and Vascular Dementia: The Eurodem Studies. Eurodem Incidence Research Group. Neurology. 1999;53(9):1992-7.

  • Tejada-Vera, B. (2013). Mortality from Alzheimer's Disease in the United States: Data for 2000 and 2010. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.

  • Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer Disease in the US population: Prevalence Estimates Using the 2000 census. Arch. Neurol. 2003;60(8):1119-22.

  • "Profiles of General Demographic Characteristics, 2000 Census of Population and Housing, United States" (PDF). U.S. Census Bureau. 2001. Archived from the original on 19 August 2008. Retrieved 2008-08-27.

  • Ferri CP. Global Prevalence of Dementia: A Delphi Consensus Study. Lancet. 2005;366(9503):2112-7.

  • World Health Organization (2006). Neurological Disorders: Public Health Challenges. Switzerland: World Health Organization. pp. 204-207.

  • Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age and Ageing, 2012, volume 41, supplement 3, pages iii 35-40. Reprint of original 1972 paper published online

  • Alzheimer's Association. Cognitive assessment. Information on Alzheimer's disease for healthcare professionals. Published online, accessed November 1st, 2013.

  • NICE. Diagnosis and assessment of dementia. In: Dementia: Supporting people with dementia and their carers in health and social care, NICE clinical guideline. London, UK: National Institute for Health and Care Excellence, November 2006.

  • Alzheimer's Society. The mini mental state examination (MMSE). Fact sheet published online, accessed November 1st, 2013.

  • Medicinenet.com Prevention

  • www.nhs.uk


Abstract Views: 435

PDF Views: 3




  • A Review on Alzheimer's Disease

Abstract Views: 435  |  PDF Views: 3

Authors

D. Rajesh Kumar
Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, India
M. Siva Shankar
Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt.), Andhra Pradesh India, India
P. Prathap Reddy
Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt.), Andhra Pradesh India, India
B. Ram Sarath Kumar
SIMS College of Pharmacy, Guntur, Andhra Pradesh, India
N. Sumalatha
SIMS College of Pharmacy, Guntur, Andhra Pradesh, India

Abstract


Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. More than 25 million people in the world today are affected by dementia, most suffering from Alzheimer's disease. There are three stages of the condition mild, moderate and severe. The symptoms are also varies from stage to stage. Some of the causes of this disease includes age, family history, Down's syndrome and vascular disease. Mainly it occurs due to presence of extracellular amyloid plaques and intracellular neurofibrillary tangles. Diagnosis can be done by using CT scan, MRI scan and Cognitive tests. Cholinesterase inhibitors and partial glutamate antagonists are used for the treatment. It can be prevented by performing some of activities like reading, writing and learning foreign languages.

Keywords


Alzheimer's Disease, Dementia, Down's Syndrome, Amyloid Plaques and Cholinesterase Inhibitors.

References